Literature DB >> 224447

Effects of serum and cations on the selective release of granular proteins from human netrophils during phagocytosis.

P Venge, R Hällgren, G Stålenheim, I Olsson.   

Abstract

The extracellular release from human neutrophils of the primary (azurophil) granule constituents, myeloperoxidase (MPO), chymotrypsin-like cationic protein (CCP), collagenase and lysozyme, and the secondary (specific) granule constituents, lactoferrin and lysozyme, was measured during ingestion of staphylococcus protein-A-IgG complexes. In buffer, lactoferrin release was consistently higher than that of the other protein. In serum, lactoferrin release increased concomitantly with ingestion, whereas the rate of lysozyme and especially of MPO release were stimulated to a higher degree than ingestion. Magnesium (0.5--2 mM) was more potent than calcium (0.5--2 mM) in promoting release but these cations worked synergistically. Zinc (0.5--4 mM) was found to be a potent and selective inhibitor of collagenase release. Manganese (0.25--4 mM), which inhibited the ingestion of SpA-IgG complexes, also inhibited release of CCP, collagenase, lysozyme and MPO, but actually stimulated lactoferrin release. The data suggests that lactoferrin and lysozyme may be confined to distinct granule populations or else released in a different fashion from the granules. When the effects on release of primary granule proteins are concerned it is suggested that the dissociation of binding of various agents to an anionic granule matrix may be affected differently by various cations.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 224447     DOI: 10.1111/j.1600-0609.1979.tb00426.x

Source DB:  PubMed          Journal:  Scand J Haematol        ISSN: 0036-553X


  17 in total

1.  Human neutrophil lipocalin is a unique marker of neutrophil inflammation in ulcerative colitis and proctitis.

Authors:  M Carlson; Y Raab; L Sevéus; S Xu; R Hällgren; P Venge
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

2.  Neutrophil phagocytosis in sarcoidosis. Reduced C3b receptor-mediated phagocytosis in active and silent sarcoidosis.

Authors:  B Schmekel; L Håkansson; R Hällgren; E Nou; G Stålenheim; P Venge
Journal:  Clin Exp Immunol       Date:  1985-04       Impact factor: 4.330

3.  Ocular symptoms, tear film stability, nasal patency, and biomarkers in nasal lavage in indoor painters in relation to emissions from water-based paint.

Authors:  Gunilla Wieslander; Dan Norbäck
Journal:  Int Arch Occup Environ Health       Date:  2010-06-15       Impact factor: 3.015

4.  Identification of a serum-derived promotor of granulocyte granule secretion: study on a patient with chronic pruritus.

Authors:  P Venge; M Boberg; L Håkansson; C Peterson
Journal:  Immunology       Date:  1982-03       Impact factor: 7.397

5.  Characterization of canine neutrophil granules.

Authors:  R T O'Donnell; B R Andersen
Journal:  Infect Immun       Date:  1982-10       Impact factor: 3.441

6.  Kinetic studies of neutrophil phagocytosis. V. studies on the co-operation between the Fc and C3b receptors.

Authors:  L Håkansson; P Venge
Journal:  Immunology       Date:  1982-12       Impact factor: 7.397

7.  Kinetic studies of phagocytosis. IV. Cellular defects and humoral inhibition as causes of impaired neutrophil phagocytosis in sarcoidosis.

Authors:  R Hällgren; L Håkansson; B Schmekel; G Stålenheim; P Venge
Journal:  Clin Exp Immunol       Date:  1982-01       Impact factor: 4.330

8.  Increased in vivo secretory activity of neutrophil granulocytes in patients with psoriasis and palmoplantar pustulosis.

Authors:  A Lundin; L Håkansson; R Hällgren; G Michaëlsson; P Venge
Journal:  Arch Dermatol Res       Date:  1985       Impact factor: 3.017

9.  Ankylosing spondylitis: a chronic inflammatory disease with iron overload in granulocytes and platelets.

Authors:  N Feltelius; U Lindh; P Venge; R Hällgren
Journal:  Ann Rheum Dis       Date:  1986-10       Impact factor: 19.103

10.  Self-labeling of human polymorphonuclear leucocyte myeloperoxidase with 125iodine.

Authors:  G Deby-Dupont; J Pincemail; A Thirion; C Deby; M Lamy; P Franchimont
Journal:  Experientia       Date:  1991-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.